Long-term Results of Percutaneous Left Atrial Closure at Brest University Hospital (CLAPOT)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

120 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-02-01

Study Completion Date

2025-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Atrial Fibrillation represents an important risk of cardioembolic stroke. In more than 90% of cases, thrombus originate in the left atrial appendage. Therefore guidelines recommend the anticoagulation of patients with atrial fibrillation and a significant cardioembolic risk, predicted by the CHA2DS2VASc score.

However, serious bleeding complications may definitively contraindicate the use of anticoagulants.

For those patients, percutaneous Left Atrial Appendage Occlusion (LAAO) has became a recommended alternative to prevent the thrombus formation and reduce the risk of cardioembolic events.

In the CHU of Brest, more than 120 patients have been treated with LAAO for the last 8 years with two different occluder devices : WATCHMAN®, Boston Scientifc and AMPLATZER Amulet®, Abbott Laboratories.

This retrospective longitudinal observational study named CLAPOT (CHU of Brest' Left Atrial Appendage Percutaneous Occlusion Treatment) aims to evaluate the long term results of this procedure for effectiveness and safety and to compare the results between the two devices (Watchman and Amplatzer).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years

NCT05387954

Cryptogenic Ischemic Stroke Patent Foramen Ovale

RECRUITING PHASE3

Endovascular Therapy for Large Core Patients With Uncertain Response to Thrombectomy

NCT06961487

Stroke, Acute Ischemic Stroke, Acute

ENROLLING_BY_INVITATION NA

Avoiding Anticoagulation After IntraCerebral Haemorrhage

NCT03243175

Intracerebral Hemorrhage Atrial Fibrillation Microhaemorrhage

RECRUITING PHASE3

Stent Thrombosis After Tandem Lesions Thrombectomy

NCT03588780

Acute Stroke With Large Vessel Occlusion

UNKNOWN

Pulmonary Embolism and Stroke in Patient With Patent Foramen Ovale

NCT01216423

Recent Stroke Pulmonary Embolism Patent Foramen Ovale

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Atrial Fibrillation Cardioembolic Stroke Left Atrial Appendage Thrombosis Anticoagulant-induced Bleeding

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Major
* Non opposition
* All patients with non-valvular atrial fibrillation and a definitive contraindication to anticoagulants who underwent left atrial appendage occlusion in the CHU of Brest between December 2014 and August 2023